A Phase I clinical study of RVT-1401 (HL161) as a subcutaneous injectable.
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2018
At a glance
- Drugs HL 161 (Primary)
- Indications Lupus nephritis; Myasthenia gravis; Neuromyelitis optica; Pemphigus
- Focus Adverse reactions
- 10 Jul 2018 According to a Roivant Sciences media release, preliminary clinical data from this study will be presented today at the First Annual Pipeline Day of the Company.
- 13 Sep 2017 New trial record
- 12 Sep 2017 According to a HanAll Biopharma media release, company is planning to initiate this trial in late 2017.